132 related articles for article (PubMed ID: 16167009)
1. New antiemetic agents.
Gralla R
Clin Adv Hematol Oncol; 2005 May; 3(5):350-2, 382. PubMed ID: 16167009
[No Abstract] [Full Text] [Related]
2. Antiemetic drugs.
Cranwell-Bruce L
Medsurg Nurs; 2009; 18(5):309-13; quiz 314. PubMed ID: 19927970
[No Abstract] [Full Text] [Related]
3. [Type-3 serotonin receptor blockaders (5-HT3)--a new class of antiemetic preparations].
Legeza VI
Eksp Klin Farmakol; 1994; 57(4):72-5. PubMed ID: 7950795
[No Abstract] [Full Text] [Related]
4. Update on the management of chemotherapy-related nausea and vomiting: an emphasis on the new class of agents--neurokinin-1 receptor antagonists.
Gralla R
Clin Adv Hematol Oncol; 2006 Jul; 4(7):507-8. PubMed ID: 17147235
[No Abstract] [Full Text] [Related]
5. In search of the ideal antiemetic.
Seegenschmiedt MH
Acta Oncol; 2004 Sep; 43 Suppl 15():13-8. PubMed ID: 15370625
[No Abstract] [Full Text] [Related]
6. [Individually risk-adapted antiemetic step therapy].
Bremer K
Dtsch Med Wochenschr; 1994 Apr; 119(16):598-604. PubMed ID: 8162844
[No Abstract] [Full Text] [Related]
7. [Neurokinin antagonists as antiemetics].
Heinzl S
Med Monatsschr Pharm; 2003 Oct; 26(10):336-7. PubMed ID: 14587153
[No Abstract] [Full Text] [Related]
8. Chemotherapy-induced nausea and vomiting.
Lohr L
Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612
[TBL] [Abstract][Full Text] [Related]
9. Antiemetics: an update and the MASCC guidelines applied in clinical practice.
Herrstedt J
Nat Clin Pract Oncol; 2008 Jan; 5(1):32-43. PubMed ID: 18097455
[TBL] [Abstract][Full Text] [Related]
10. Blueprint for the control of radiation-induced nausea and vomiting. Discussion.
Horiot JC
Acta Oncol; 2004 Sep; 43 Suppl 15():23-4. PubMed ID: 15370627
[No Abstract] [Full Text] [Related]
11. Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
Trigg ME; Inverso DM
Bone Marrow Transplant; 2008 Oct; 42(8):501-6. PubMed ID: 18724391
[TBL] [Abstract][Full Text] [Related]
12. Aprepitant (EMEND): the role of substance P in nausea and vomiting.
Prommer E
J Pain Palliat Care Pharmacother; 2005; 19(3):31-9. PubMed ID: 16219609
[TBL] [Abstract][Full Text] [Related]
13. Anti-emetic therapy in cancer chemotherapy: current status.
Herrstedt J; Dombernowsky P
Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
[TBL] [Abstract][Full Text] [Related]
14. [Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting].
Durand JP; Madelaine I; Scotté F
Bull Cancer; 2009 Oct; 96(10):951-60. PubMed ID: 19734117
[TBL] [Abstract][Full Text] [Related]
15. The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting.
Apfel CC; Malhotra A; Leslie JB
Curr Opin Anaesthesiol; 2008 Aug; 21(4):427-32. PubMed ID: 18660647
[TBL] [Abstract][Full Text] [Related]
16. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
17. Use of placebos in delayed-emesis studies.
Navari RM
J Clin Oncol; 1999 May; 17(5):1648-50. PubMed ID: 10334561
[No Abstract] [Full Text] [Related]
18. Current treatment patterns for radiation-induced nausea and vomiting.
Kinay M
Acta Oncol; 2004 Sep; 43 Suppl 15():9-12. PubMed ID: 15370624
[No Abstract] [Full Text] [Related]
19. Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities.
Navari RM
Curr Opin Investig Drugs; 2008 Jul; 9(7):774-85. PubMed ID: 18600583
[TBL] [Abstract][Full Text] [Related]
20. [From cocaine to innovative antiemetics. The medicinal chemistry of 5-ht3 receptor antagonists].
Zettl H; Schubert-Zsilavecz M; Siebert CD
Pharm Unserer Zeit; 2007; 36(5):354-61. PubMed ID: 17722162
[No Abstract] [Full Text] [Related]
[Next] [New Search]
